Literature DB >> 27587361

Anti-GP2 IgA: a biomarker for disease severity and/or cholangiocarcinoma in primary sclerosing cholangitis?

Sumera Rizvi1, Ju Dong Yang1, Gregory J Gores1.   

Abstract

Entities:  

Keywords:  CHOLANGIOCARCINOMA; PRIMARY SCLEROSING CHOLANGITIS

Mesh：

Substances：

Year:  2016        PMID： 27587361      PMCID： PMC5574160          DOI： 10.1136/gutjnl-2016-312492

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   31.793


× No keyword cloud information.
  9 in total

1.  Pancreatic Autoantibodies Against CUZD1 and GP2 Are Associated with Distinct Clinical Phenotypes of Crohn's Disease.

Authors:  Maike Anna Michaels; Sebastian Torben Jendrek; Tobias Korf; Thomas Nitzsche; Bianca Teegen; Lars Komorowski; Stefanie Derer; Torsten Schröder; Florian Baer; Henrik Lehnert; Jürgen Büning; Klaus Fellerman; Christian Sina
Journal:  Inflamm Bowel Dis       Date:  2015-12       Impact factor: 5.325

2.  Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis.

Authors:  Sebastian Torben Jendrek; Daniel Gotthardt; Thomas Nitzsche; Laila Widmann; Tobias Korf; Maike Anna Michaels; Karl-Heinz Weiss; Evaggelia Liaskou; Mette Vesterhus; Tom Hemming Karlsen; Swantje Mindorf; Peter Schemmer; Florian Bär; Bianca Teegen; Torsten Schröder; Marc Ehlers; Christoph Matthias Hammers; Lars Komorowski; Hendrik Lehnert; Klaus Fellermann; Stefanie Derer; Johannes Roksund Hov; Christian Sina
Journal:  Gut       Date:  2016-07-12       Impact factor: 23.059

3.  The gut-adherent microbiota of PSC-IBD is distinct to that of IBD.

Authors:  Mohammed Nabil Quraishi; Martin Sergeant; Gemma Kay; Tariq Iqbal; Jacqueline Chan; Chrystala Constantinidou; Palak Trivedi; James Ferguson; David H Adams; Mark Pallen; Gideon M Hirschfield
Journal:  Gut       Date:  2016-04-19       Impact factor: 23.059

4.  The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis.

Authors:  Cynthia Levy; James Lymp; Paul Angulo; Gregory J Gores; Nicholas Larusso; Keith D Lindor
Journal:  Dig Dis Sci       Date:  2005-09       Impact factor: 3.199

5.  Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma.

Authors:  Emmanouil Sinakos; Amy K Saenger; Jill Keach; W Ray Kim; Keith D Lindor
Journal:  Clin Gastroenterol Hepatol       Date:  2011-02-17       Impact factor: 11.382

Review 6.  Primary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management.

Authors:  Sumera Rizvi; John E Eaton; Gregory J Gores
Journal:  Clin Gastroenterol Hepatol       Date:  2015-06-05       Impact factor: 11.382

7.  The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls.

Authors:  Martin Kummen; Kristian Holm; Jarl Andreas Anmarkrud; Ståle Nygård; Mette Vesterhus; Marte L Høivik; Marius Trøseid; Hanns-Ulrich Marschall; Erik Schrumpf; Bjørn Moum; Helge Røsjø; Pål Aukrust; Tom H Karlsen; Johannes R Hov
Journal:  Gut       Date:  2016-02-17       Impact factor: 23.059

8.  Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders.

Authors:  Jochen Metzger; Ahmed A Negm; Ruben R Plentz; Tobias J Weismüller; Jochen Wedemeyer; Tom H Karlsen; Mohammed Dakna; William Mullen; Harald Mischak; Michael P Manns; Tim O Lankisch
Journal:  Gut       Date:  2012-05-12       Impact factor: 23.059

Review 9.  Update on biomarkers of hepatocellular carcinoma.

Authors:  Roongruedee Chaiteerakij; Benyam D Addissie; Lewis R Roberts
Journal:  Clin Gastroenterol Hepatol       Date:  2013-11-23       Impact factor: 11.382
  9 in total
  1 in total

1.  Salivary secretory immunoglobulin A reactivity: a comparison to cortisol and α-amylase patterns in the same breast cancer survivors.

Authors:  Maude Lambert; Marie-Ève Couture-Lalande; Kelly Brennan; Aldin Basic; Sophie Lebel; Catherine Bielajew
Journal:  Contemp Oncol (Pozn)       Date:  2018-09-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.